Translate the text from Welsh to English.



 
Mae’r rhai pobl yn wynebu mwy o risg o fynd yn ddifrifol wael os byddant yn cael prawf positif ar gyfer y feirws. Mae’r rhain yn cynnwys pobl â chanser, pobl â Syndrom Down, pobl sydd wedi cael trawsblaniad a phobl sy’n cymryd meddyginiaethau sy’n gwanhau eu system imiwnedd.    

  

Mae triniaethau COVID newydd wedi bod ar gael yn y gymuned ers mis Rhagfyr i helpu i atal y grŵp hwn o bobl rhag cael salwch mwy difrifol os ydynt yn dal y coronafeirws.  

  

Hyd yma, mae mwy na 700 o gleifion o bob rhan o Gymru wedi cael eu trin yn llwyddiannus â thriniaethau gwrthgyrff monoclonaidd neu'r feddyginiaeth wrthfeirol molnwpirafir  

  

O hyn ymlaen byddant hefyd yn cael cynnig y driniaeth gyfunol newydd nirmatrelfir/ritonafir (Paxlovid). Yn wahanol i’r driniaeth gwrthgyrff monoclonaidd sotromifab, sy’n cael ei rhoi yn ysbyty, bydd modd i Paxlovid gael ei gymryd gartref.  

  

Mae treialon clinigol wedi dangos bod cymryd Paxlovid o fewn pum diwrnod i ddatblygu symptomau COVID yn golygu bod 88 y cant yn llai o risg y bydd angen i’r unigolyn gael ei dderbyn i’r ysbyty.    

  

Bydd Gwasanaeth Gwrthfeirol Cenedlaethol Cymru yn cysylltu â’r rheini sy’n gymwys i gael Paxlovid drwy eu ffonio neu anfon neges destun atynt o fewn 48 awr i ganlyniad positif gael ei gofnodi ar gyfer prawf llif unffordd neu brawf PCR.   

  

Bydd fferyllwyr sydd wedi cael hyfforddiant arbennig yn gofyn cwestiynau am y meddyginiaethau y mae unigolion yn eu cymryd er mwyn penderfynu pa driniaeth sydd fwyaf priodol iddynt yn glinigol. Os bydd Paxlovid yn driniaeth addas, bydd yn cael ei anfon i gartref yr unigolyn o fewn 24 awr. Os na fydd Paxlovid yn addas, bydd sotrofimab yn parhau i gael ei gynnig.  

  

Mae pobl nad ydynt yn y grŵp risg uchaf yn dal i allu cael y driniaeth wrthfeirol molnwpirafir drwy’r astudiaeth PANORAMIC, a bydd Paxlovid yn cael ei ychwanegu ar yr astudiaeth yn nes ymlaen y mis hwn. Mae’r astudiaeth yn agored i unrhyw un dros 50 oed neu i  unigolion 18\-49 oed sydd â chyflyrau iechyd penodol sy’n bodoli eisoes. Mae dros 8,000 o bobl ar draws y DU wedi cael eu recriwtio i’r astudiaeth ers iddi ddechrau ym mis Rhagfyr.  

  

Dywedodd y Gweinidog Iechyd a Gwasanaethau Cymdeithasol, Eluned Morgan:



> “Dw i’n falch iawn ein bod yn gallu cynyddu nifer y triniaethau sydd ar gael i’r bobl fwyaf agored i niwed yng Nghymru os byddan nhw’n dal COVID\-19\.  
> 
>   
> 
> “Mae meddyginiaethau gwrthfeirol ar eu mwyaf effeithiol pan fydd pobl yn cael eu trin cyn gynted â phosibl, a dyna pam rydyn ni bellach yn cysylltu â phobl ar ôl i ganlyniad positif gael ei gofnodi ar gyfer prawf llif unffordd yn ogystal â phrawf PCR.   
> 
>   
> 
> “I’r rhan fwyaf o bobl, cael cwrs llawn o’r brechlyn, ac yna ddos atgyfnerthu, sy’n rhoi’r amddiffyniad mwyaf effeithiol yn erbyn salwch difrifol. Serch hynny mae nifer bach o bobl nad ydyn nhw’n cael ymateb cyflawn i’r brechlyn, ac mae triniaethau gwrthfeirol a thriniaethau gwrthgyrff yn cynnig amddiffyniad pellach i’r grŵp hwn.”


Dywedodd Prif Fferyllydd y Gwasanaeth Gwrthfeirol Cenedlaethol, Alana Adams:



> “Mae mwy na 700 o bobl yng Nghymru sydd yn y grŵp risg uchel iawn eisoes wedi cael eu trin â thriniaethau gwrthfeirol a thriniaethau gwrthgyrff er mwyn eu hamddiffyn rhag canlyniadau mwyaf difrifol COVID\-19\.  
> 
>   
> 
> “Fel arbenigwyr mewn meddyginiaethau, mae gan y fferyllwyr sy’n gweithio yn y Gwasanaeth Gwrthfeirol Cenedlaethol yr wybodaeth a’r arbenigedd i helpu pobl i benderfynu pa driniaeth yw’r dewis mwyaf priodol iddynt.  
> 
>   
> 
> “Mae tystiolaeth bod Paxlovid yn cael mwy o effaith na’r meddyginiaethau gwrthfeirol rydyn ni’n eu defnyddio eisoes o ran lleihau nifer y rheini sy’n gorfod cael eu derbyn i’r ysbyty, ac yn wahanol i driniaethau gwrthgyrff gellir ei gymryd gartref.”







Translation:


 
People who are at the greatest risk of becoming seriously ill if they test positive for the virus include people with cancer, people with Down’s syndrome, people who have had a transplant and people who are taking medicines that suppress their immune system.  

  

New COVID treatments have been available in the community since December to help prevent this group of people developing more serious disease if they contract coronavirus.


To date, more than 700 patients from all parts of Wales have been successfuly treated with monoclonal antibody treatments or the antiviral medicine molnupiravir.   

  

They will also now be offered the new combination treatment nirmatrelvir/ritonavir (Paxlovid) which unlike the monoclonal antibody treatment sotrovimab which is given in hospitals can be taken at home.   

  

Clinical trials show when Paxlovid is taken within five days of COVID symptoms developing it reduced the risk of hospitalisation from COVID\-19 by 88 per cent.   

  

People who are eligible for treatment with Paxlovid will be contacted by telephone call or text message from Wales’ National Antiviral Service within 48 hours of reporting a positive lateral flow test result or a positive PCR test.   

  

Specially trained pharmacists will ask questions about the medicines they take to determine which treatment is the most clinically appropriate for them.  If Paxlovid is an appropriate treatment, it will be delivered to their home within 24 hours.  If Paxlovid isn’t suitable they will continue to be offered sotrovimab.  

  

People who are not in the highest risk group are still able to access the antiviral treatment molnupiravir through the PANORAMIC study and Paxlovid is being added to the study later this month. The study is open to anyone over the age of 50 or between 18 and 49 with certain underlying health conditions.    

  

Across the UK, more than 8,000 people have been recruited to the study since it began in December.


Minister for Health and Social Services Eluned Morgan said:



> “I am delighted we are increasing the range of treatment options available to the most vulnerable people in Wales if they get COVID\-19\.  
> 
>   
> 
> “Antiviral medicines are more effective if people are treated as soon as possible, which is why we are now contacting people after they report a positive lateral flow test result as well as after a PCR test.   
> 
>   
> 
> “For most people having a full course of vaccination and a booster offers the most protection against severe illness, however a small number of people do not have a full response to the vaccine.  Antiviral and antibody treatments offer further protection for this group”


Alana Adams, Principal Pharmacist at the National Antiviral Service said:



> “More than 700 people in Wales who are at very high risk have already been treated with antiviral and antibody treatments to protect them from the most severe consequences of COVID\-19\.  
> 
>   
> 
> “As experts in medicines the pharmacists working in the National Antiviral Service have the knowledge and expertise to help people decide which treatment option is most appropriate for them.  
> 
>   
> 
> “Paxlovid has been shown to have a greater effect on reducing hospitalisation than the antiviral medicines we use already, and unlike antibody treatments it can be taken at home.”